Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists

• US 20060147450A1
• Filed: 10/06/2003
• Published: 07/06/2006
• Est. Priority Date: 10/04/2002
• Status: Abandoned Application

• Current Assignee: Rinat Neuroscience Corp. (Pfizer Inc.)
• Original Assignee: Rinat Neuroscience Corp. (Pfizer Inc.)
• Inventors: Shelton, David L
• Application Number:
  US10/529,835
• Publication Number:
  US 20060147450A1
• Time in Patent Office: Days
• US Class Current: 424/145.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators

Abstract

This invention relates to the field of cardiac disease. More specifically, the invention relates to methods using an NGF antagonist for treating and preventing cardiac arrhythmia and methods of preventing death due to cardiac arrhythmia.

Claims

1. A method of treating a cardiac arrhythmia in an individual comprising administering an effective amount of an NGF antagonist.

2. The method of claim 1, wherein said cardiac arrhythmia comprises sustained ventricular tachycardia.

3. The method of claim 1, wherein said cardiac arrhythmia comprises non-sustained ventricular tachycardia.

4. The method of claim 1, wherein said cardiac arrhythmia comprises ventricular fibrillation.

5. The method of claim 1, wherein said cardiac arrhythmia is associated with sudden cardiac death.

6. The method of claim 1, wherein the NGF antagonist is an anti-NGF antibody.

7. The method of claim 6, wherein the anti-NGF antibody binds to human NGF.

8. The method of claim 6, wherein the binding affinity of the anti-NGF antibody is about 0.1 nM or less than about 0.1 nM.